Bedfont® now focuses on supporting clinical research, debuting at the 9th annual Outsourcing in Clinical Trials DACH in Basel.
Bedfont® Scientific Limited, a world leader in breath analysis with 50 years of experience manufacturing medical devices, has quietly supported respiratory research around the world and is set to make its debut at its first clinical trial-focused event in November, taking the next step toward a dedicated focus on supporting clinical trials and clinical research teams, marking the beginning of a new chapter at Bedfont®.
Outsourcing in Clinical Trials (OCT) DACH is an annual conference that brings together professionals involved in the planning, management and outsourcing of clinical trials across Germany, Austria and Switzerland. As Bedfont® expands its focus on supporting clinical trials, attending OCT DACH is the perfect opportunity to engage directly with the professionals shaping the future of clinical research.
“The future of respiratory medicine depends on robust clinical research. As biomarkers continue to play an increasingly important role in clinical trials, researchers need partners they can rely on for both scientific expertise and dependable technology.” Says Jason Smith, CEO at Bedfont®, “Building on our experience in respiratory diagnostics and the established use of NObreath® in clinical studies, we are excited to strengthen our support for the clinical research community and look forward to building relationships with the organisations leading respiratory studies at OCT DACH in November.”
The NObreath® FeNO device has been aiding asthma diagnosis and management for over 15 years. Designed for reliability, NObreath® provides accurate, repeatable FeNO measurements for long-term studies, making it the perfect choice for clinical trials. You can find the Bedfont® team at stand 10b for live demonstrations of NObreath® and to see how straightforward it is to incorporate FeNO testing into clinical trial protocols and patient visits.
To learn more about NObreath® and Bedfont’s attendance at this year’s conference, visit the website here.
Bedfont®, a world leader in breath analysis, announces its acquisition of coVita™, building on 16 years of partnership, market knowledge, and established infrastructure to support global expansion.
Bedfont® Scientific Limited, a leading MedTech company with 50 years of experience designing and manufacturing medical breath analysis devices, has taken the next step in its global expansion by acquiring coVita™ LLC. The acquisition positions Bedfont® to further penetrate the US market with its innovative breath analysis devices, including the NObreath® Fractional exhaled Nitric Oxide (FeNO) device.
coVita™, a US medical device company based in The Woodlands, Texas, has served as Bedfont’s US distributor for more than 16 years, helping expand its breath analysis technologies across the US. With its extensive knowledge, coVita™ has provided valuable insight into the US healthcare market, helping Bedfont® understand local needs, navigate market opportunities, and strengthen its presence across the region.
“This acquisition represents an exciting new chapter for Bedfont® and builds on the strong relationship we have developed with coVita™ over many years. At the heart of everything we do is our commitment to improving healthcare through accessible, simple and non-invasive breath analysis.” Says Jason Smith, CEO of Bedfont®. “By bringing our expertise together and strengthening our presence in the US, we can reach more healthcare professionals, researchers and ultimately patients, helping to improve access to breath testing and support better healthcare outcomes.”
“For more than 16 years, we’ve had the privilege of bringing Bedfont’s breath analysis technology to healthcare professionals across the US, and we’ve seen firsthand the difference it makes in clinical practice,” says Jason Aversano, Co-founder and CEO of coVita™. “Becoming part of Bedfont® is a natural next step in that journey. Our leadership and team will remain the same, so our customers can expect the same people and the same dedicated local support they know and trust. What changes is the pace. With Bedfont’s full resources behind us, we’ll be able to grow faster, reach more clinicians and support more research across the US and world.”
After Keensight’s majority stake in Bedfont® in 2025, this marks another new chapter in Bedfont’s history. The acquisition allows Bedfont® to continue building on coVita’s success, especially in the US FeNO market. As Bedfont® puts more focus on clinical research, a US base provides access to a major clinical research market and enables localised distribution, training, and technical support.
The announcement coincides with coVita’s attendance at this year’s CHEST annual meeting. The event brings together healthcare professionals interested in pulmonary, critical care, and sleep medicine. Taking place between the 18th and 21st of October in Phoenix, Arizona, coVita™ will be at booth 1263, showcasing the innovative NObreath® FeNO device.
Building on its long-standing partnership with coVita™, Bedfont® combines its breath analysis expertise with established US market knowledge and infrastructure, strengthening NObreath’s proposition for multicentre clinical trials and improving access to objective testing to aid asthma diagnosis and management. To learn more about Bedfont®, visit the website here.
World leaders in breath analysis will showcase its Gastrolyzer® range at one of the leading international events for digestive health.
Bedfont® Scientific Limited, a world leader in breath analysis with 50 years of industry experience, is pleased to attend this year’s United European Gastroenterology (UEG) Week in Barcelona to showcase the innovative Gastrolyzer® range of devices. As a leading international congress for the digestive health community, UEG focuses on scientific research, education, clinical practice, and industry innovation. With over 30 years of expertise in hydrogen and methane breath testing (HMBT) with the Gastrolyzer® for gastrointestinal investigation, Bedfont® aims to improve awareness of its non-invasive breath testing technology for gastrointestinal disorders.
Established in 1992, UEG Week has become a leading congress for gastroenterology and digestive health, with over 11,000 people attending last year’s congress in Berlin. This year, the congress will be held at Fira Gran Via in Barcelona from 17th to 20th October. It will bring together the global digestive health community to share the latest research, clinical developments and innovations in Gastroenterology.
Jason Smith, CEO at Bedfont®, comments, “Improving access to effective digestive health testing is an important global priority, with more than 40% of people worldwide estimated to experience functional gastrointestinal disorders1. At Bedfont®, we believe breath analysis plays an important role in helping healthcare professionals investigate digestive health in a simple, non-invasive way. UEG Week provides a fantastic opportunity to connect with the global gastroenterology community, share knowledge and demonstrate how our Gastrolyzer® range can help improve patient care.”
For over 35 years, the Gastrolyzer® range has helped detect gastrointestinal disorders, one breath at a time. The range includes the Gastro+™, a hand-held portable hydrogen device, and the GastroCH4ECK® desktop hydrogen and methane device, which can conduct remote testing.
Joining the Bedfont® team in Barcelona will be Dr Jafar Jafari, Head of Upper Gastrointestinal (GI) Physiology at Guy’s and St Thomas’, founder of GI Cognition, and member of the Bedfont® Medical Advisory Board. He will be there to discuss his book, ‘The Essential Guide to Hydrogen and Methane Breath Testing ’, and provide invaluable clinical expertise on the stand. You can find the team at stand 29 from 18th to 20th October, where you can find out more about the Gastrolyzer® range and see it in action with live demonstrations. For more information, visit the website here.
References:
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology [Internet]. 2020 Apr [cited 2026 Sept 9];160(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32294476/
Smokerlyzer® registration with Medicah S.A.S in Colombia boosts quit-smoking services in the region.
Bedfont® Scientific Limited, an innovative MedTech company with nearly 50 years of experience in the breath analysis industry, is pleased to collaborate with Medicah S.A.S through a new registration for the Smokerlyzer® range of carbon monoxide (CO) monitoring devices. The partnership aims to improve smoking cessation services across Colombia.
Bedfont® has been helping people to quit smoking with its Smokerlyzer® range for over 40 years. The Smokerlyzer® range measures levels of CO in parts per million (ppm) on exhaled breath, helping to establish a person’s smoking status. Monitoring CO levels and seeing them drop during a quit attempt provides smokers with a motivational aid to quit smoking.
Medicah S.A.S, a distributor of medical technology, supports hospitals, clinics and diagnostic providers through product supply and after-sales service. Already a distributor of the Bedfont® NObreath® Fractional exhaled Nitric Oxide (FeNO) device, Medicah S.A.S. is chosen for its shared commitment to improving patient outcomes, with the Smokerlyzer® range an important addition to its product catalogue.
“We are delighted to expand our partnership with Medicah through the registration of our Smokerlyzer® range in Colombia. Having successfully worked together to bring our NObreath® to healthcare professionals across the region, we are proud that this latest addition strengthens Medicah’s respiratory diagnostics portfolio and reinforces our shared commitment to improving patient care.” Said Jason Smith, CEO at Bedfont®.
CO monitoring plays a vital role in smoking cessation programmes and respiratory health management, providing clinicians with an objective and immediate measure to support behaviour change and treatment decisions.
Whilst Colombia is considered a relatively low-smoking country in Latin America, the latest registration of the Smokerlyzer® range of CO monitoring devices provides an additional tool, making this technology more widely available, allowing healthcare providers to deliver more effective interventions and improve patient outcomes throughout Colombia and the surrounding areas.
To learn more about the Smokerlyzer® range of CO monitoring devices, visit the website here.
Showcasing the NObreath® and Smokerlyzer® range while connecting with research teams and global distribution partners at Europe’s leading respiratory congress.
Bedfont® Scientific Limited, a world leader in breath analysis, is excited to be attending this year’s European Respiratory Society (ERS) Congress in Barcelona. With over 50 years of experience in the design and manufacture of medical breath analysis devices, Bedfont® looks to connect with professionals in healthcare and clinical research to share its innovative Fractional exhaled Nitric Oxide (FeNO) and carbon monoxide (CO) monitoring technology.
The ERS Congress is the world’s largest international meeting dedicated to respiratory medicine, bringing together approximately 20,000 clinicians, researchers, healthcare professionals and industry leaders from across the world. This year’s congress takes place in Barcelona from the 5th to the 9th of September, providing a platform for sharing the latest scientific advances, promoting collaboration and driving innovation in respiratory care.
This year’s theme is “United for better breathing: partnership between patients, clinicians and researchers.” With Bedfont® looking to strengthen its commitment to respiratory clinical research, ERS provides the perfect platform to connect with industry professionals and showcase its innovations.
Jason Smith, CEO at Bedfont®, comments, “ERS Congress is one of the most important events in the respiratory calendar, bringing together the very people driving innovation in respiratory medicine. We’re excited to return to Barcelona to showcase our NObreath® FeNO device and Smokerlyzer® range, while strengthening relationships with our distributor network and connecting with research teams and healthcare professionals. As Bedfont® continues to expand its presence in medical research, we’re looking forward to discussing how our trusted respiratory monitoring solutions can further support studies and ultimately improve patient care around the world.”
The Bedfont® team will be at Stand R.19 from the 6th to the 9th of September, where visitors can explore the NObreath® and Smokerlyzer® devices and meet the experts behind them. Joining the team is renowned respiratory nurse and clinical leader, Carol Stonham MBE, who will be on the stand to share her expertise and provide valuable clinical insight into the role of FeNO testing in respiratory care. Carol will be available alongside Bedfont’s Clinical Research Partnerships Manager, Hannah Vince-Drew, to answer questions and discuss the application of FeNO testing in both clinical practice and clinical research.
The Gastrolyzer® forum has now been replaced by our Gastrolyzer® Educational Portal. The forum previously provided a space for healthcare professionals using the Gastrolyzer® devices to communicate and share knowledge.
The updated Gastrolyzer® Educational Portal has been designed to offer everything the forum did but also give quick and easy access to a wide range of resources, including:
How-to videos,
Webinars,
Case studies,
Clinical articles,
FAQs,
Practical guidance.
This valuable resource helps you get the most from our Gastrolyzer® hydrogen and methane breath testing (HMBT) devices.
If you’ve arrived here looking for the Gastrolyzer® Forum, simply visit the Educational Portal to access the latest educational resources and support materials.
If what you are looking for cannot be found in the Educational Portal, please get in touch with the Bedfont® team, who will be happy to help. You can find out more about Bedfont® here.
Over 1,200 NObreath® FeNO devices sold since the 2024 UK guideline update.
Bedfont® Scientific Limited, an innovative leader in breath analysis and Fractional exhaled Nitric Oxide (FeNO) testing for asthma care with the NObreath®, welcomes the news that over 1 million people with asthma are now using combination inhalers1 following the joint 2024 asthma guidelines from the National Institute for Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN)2. This milestone marks a significant shift in asthma management in the UK, with NObreath® sales exceeding 1,240 units since the update.
The well-known blue reliever inhaler helps control symptoms but doesn’t address the underlying airway inflammation, the key driver of asthma. Airway inflammation cannot be seen or felt, so whilst patients may not be experiencing any symptoms, the inflammation could be building below the surface, leading to an exacerbation or asthma attack. The NObreath® FeNO device can quickly measure airway inflammation, giving clinicians valuable objective insight enabling them to tailor treatment effectively.
Switching patients to combination inhalers ensures not only symptom relief but also inflammation control. The updated guideline reflects a growing emphasis on prevention-focused asthma care, including earlier anti-inflammatory treatment and reduced reliance on symptom relief alone.
“Seeing more than 1 million people now using combination inhalers marks a significant milestone in the evolution of asthma care. It reflects a growing emphasis on prevention-focused asthma care, including earlier anti-inflammatory treatment and reduced reliance on symptom relief alone. At Bedfont®, we’re proud that FeNO testing is helping support this shift towards more proactive, personalised care. Through the NObreath®, we are helping clinicians gain objective insight into airway inflammation, supporting better-informed decisions and improved long-term outcomes. Everyone deserves access to better asthma care, empowering them to live healthier lives with greater confidence and control.” Said Jason Smith, CEO at Bedfont®.
Bedfont® works closely with its UK distributor, Intermedical UK, to expand access to FeNO testing nationwide. Intermedical launched its NObreath® 3000 campaign last year, signifying a major milestone of 3,000 NObreath® sales in the UK. It also reported growing sales following the guideline update, with over 1,240 devices sold since November 2024 alone, demonstrating the impact of national guidance on asthma care.
A FeNO test with the NObreath® can assess inflammation by measuring nitric oxide (NO) levels in exhaled breath, a biomarker of airway inflammation. The test is quick, easy, and non-invasive, supporting clinicians’ decision-making and treatment plans aligned with evolving guidelines. This milestone reflects a broader shift in asthma care towards precision medicine, biomarker-driven approaches, and more personalised management, all aimed at improving patient outcomes worldwide.
The NObreath® FeNO device has been improving asthma care for over 15 years. To learn more, please visit the website here.
National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245
Almost 10 months after the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) released an updated joint guideline for asthma care and management, a major milestone has been hit. Over 1 million people are now using combination inhalers instead of relying solely on blue reliever inhalers, marking a major shift towards inflammation-focused asthma management.1
Why does this matter?
Previously, many people living with asthma relied on their blue reliever inhaler, which relieved symptoms, making them feel better quickly. The problem with this was that whilst symptoms were being addressed, the underlying airway inflammation, the main driver of their symptoms, was not being treated. If the inflammation is not treated, symptoms continue to recur, damaging quality of life and increasing over-reliance on medication.1
The problem with symptom-led asthma care.
Patients who rely heavily on Short-Acting Beta-Agonist (SABA) inhalers (rescue inhalers) may report feeling well and believe that their asthma is well controlled because regular use of their inhaler keeps their symptoms at bay.1 When, in reality, this reliance is masking the underlying issue: airway inflammation.
Airway inflammation cannot always be felt, and if left untreated, it could lead to further exacerbations, including asthma attacks.
The shift towards prevention-focused care.2
The update to the guideline placed greater emphasis on treating the underlying inflammation rather than just the symptoms, demonstrating an evolution in asthma care. The updated guidance reflects:
Earlier anti-inflammatory treatment,
Reduced SABA reliance,
Prevention of exacerbations,
More proactive asthma management.
The impact of this guidance is clear: over 1 million people now use combination inhalers to relieve symptoms and treat underlying inflammation, a significant milestone for asthma care.1
Why objective insight matters.
During routine asthma reviews, patients are typically asked about their symptoms, which rely on patient recall. Typically, people with asthma downplay their symptoms, believing that what they experience is typical of their condition.3
And whilst peak flow remains a useful tool in asthma care, it alone may not provide the full picture. It measures airflow obstruction, rather than the inflammatory activity driving asthma, demonstrating the need for objective assessment, because better asthma care starts with better insight.
The role of FeNO testing.2
Fractional exhaled Nitric Oxide (FeNO) testing provides an objective tool to measure airway inflammation. It is non-invasive, easy to do at the point of care and supports:
Diagnosis,
Inhaled corticosteroid (ICS) decisions,
Adherence assessment,
Monitoring,
Evaluation of exacerbation risk.
Aligning with the latest guidance, FeNO supports the move towards more personalised, biomarker-driven asthma care.
The NObreath® FeNO device.
The NObreath® is a modern FeNO device; it is portable and easy to use, making it perfect for primary care. Clinicians can measure a person’s airway inflammation in a short amount of time, fitting perfectly into a standard healthcare appointment. This objective insight enables clinicians to make informed decisions there and then without the need for a follow-up appointment to discuss results.
Combined with an extensive clinical history, a FeNO test with the NObreath® can aid in an asthma diagnosis and tailor treatment appropriately, providing enhanced asthma monitoring.
Precision medicine and the future of asthma care.2
Guidelines are updated as technology and research evolve to improve patient care. The latest guideline from NICE/BTS/SIGN marked a move towards:
Precision medicine,
Biomarkers
Personalised pathways
Earlier intervention,
Better outcomes.
The move towards combination inhalers marks more than a treatment change; it represents a broader evolution in how asthma is understood and managed. Objective insight can provide clinicians with a better understanding of what is going on beneath the surface, with FeNO testing supporting this objective insight and supporting future asthma care.
As asthma care continues to evolve, understanding airway inflammation will become increasingly important in helping clinicians deliver a more personalised and proactive approach.
To learn more about the NObreath® device and how FeNO testing is improving patient outcomes worldwide, visit the website here.
National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245
Bidad N, Barnes N, Griffiths C, Horne R. Understanding patients’ perceptions of asthma control: a qualitative study. European Respiratory Journal. 2018 May 17;51(6):1701346.
The congress, taking place in Istanbul, Türkiye from Friday 12th to Sunday 14th of June, is widely recognised as the world’s largest and most influential meeting dedicated to allergy and clinical immunology. It brings together thousands of clinicians, researchers and healthcare professionals from across the globe each year to share new ideas and showcase innovations in diagnostics, playing a central role in advancing research, education and patient care in allergic diseases such as asthma and food allergy.
“Attending the EAACI Congress 2026 reflects our commitment to strengthening our global network. We look forward to connecting with like-minded organisations, sharing insights into our technology, and exploring new distribution partnerships with those seeking innovative solutions.” Said Jason Smith, CEO at Bedfont®. “We see EAACI as a key opportunity to build relationships that will drive future growth in the allergy and immunology space.”
The Bedfont® team is pleased to be joined by its Turkish distributor, Teknikel, to demonstrate its Fractional exhaled Nitric Oxide (FeNO) and hydrogen and methane breath testing (HMBT) technologies, highlighting how these innovative tools can support improved diagnosis, monitoring, and the management of respiratory and gastrointestinal conditions.
The team will be at stand I03, where you can find the NObreath® FeNO device, which has been improving asthma care and management for over 15 years, providing an objective insight into airway inflammation, a key driver of asthma symptoms. And the Gastrolyzer® range of HMBT devices, which have been aiding gastrointestinal investigation for over 35 years, enabling clinicians to tailor treatment effectively.
For Bedfont®, this congress is invaluable not only for showcasing its solutions but also for engaging with partners and stakeholders as it continues to advance technology and expand its global reach. To learn more, visit the website here.
Bedfont® celebrates global expansion by delivering UK healthcare solutions to a growing global audience.
Bedfont® Scientific Limited, an innovative MedTech company that specialises in designing and manufacturing medical breath analysis devices, is thrilled to have been shortlisted in the Export Achievement category at the Science and Engineering Health Technologies Alliance (SEHTA) Healthcare Business Awards 2026.
The SEHTA Healthcare Business Awards are one of the South East’s leading healthcare innovation awards, celebrating excellence in healthcare, especially in life sciences and medical technology. Bedfont®, a world leader in breath analysis, has seen significant growth over the last decade and places a strong emphasis on international sales, with over 59% of export sales contributing to its annual turnover.
Jason Smith, CEO at Bedfont®, comments, “Being shortlisted for the Export Achievement award is a fantastic recognition of our team’s hard work and our mission to improve healthcare outcomes globally. Our international growth is a key part of our strategy, and we’re proud to represent UK innovation on the world stage.”
With a global network of over 100 distributors, Bedfont® prioritises long-term partnerships built on trust and collaboration. The company understands that entering new markets is a gradual process, requiring sustained investment in relationships and a tailored approach to each region. By adapting its service, support, and go-to-market strategy to local needs, Bedfont® ensures its solutions are both relevant and effective worldwide.
The awards ceremony, due to take place at Scale Space, Imperial College London, on Tuesday, 26th May, will bring together businesses across the South East to celebrate healthcare innovation. To find out more about Bedfont® and its innovative medical devices, visit the website here.
